All News
TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis
A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
Read Article
Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
Read Article
RA-ILD takes centre stage
Greg McDermott presented abstract 2248 on the prevalence and mortality of subpleural interstitial lung abnormalities (ILA) in RA and non-RA comparators.
https://t.co/zrg7IEhBfg https://t.co/dKACCzr4CZ
Links:
Dr. John Cush RheumNow ( View Tweet)
More Than a Conference:Life’s Lessons
By: @KDAO2011
This is my 20th year attending the ACR meeting; despite my virtual attendance, I was still able to connect w/people. I reflected on my experiences w/ the conference and wanted to share my life lessons.
https… https://t.co/9gBbaYBujc
Dr. John Cush RheumNow ( View Tweet)
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Links:
Dr. John Cush RheumNow ( View Tweet)
Sleep Quality & PsA
Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c
Links:
Dr. John Cush RheumNow ( View Tweet)
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate + pegloticase increases response rates in gout
Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents.
https://t.co/8cqsAXuzIB https://t.co/OSpf5ehiCm
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of ACR Day Two in PSA
https://t.co/FXGCPaTGX6 https://t.co/WICtjVICC2
Links:
Dr. John Cush RheumNow ( View Tweet)
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash ( @drpnash) discusses Abstract 1018 at #ACR22 Convergence.
https://t.co/Wk3ibuh9ip https://t.co/FcLjDMJCgr
Links:
Dr. John Cush RheumNow ( View Tweet)
Low-grade Proteinuria in Non Renal Lupus: Should We be Worried?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22
https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioid use in PsA and SpA
Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence
https://t.co/Doxbk7qW33 https://t.co/2UX07T2JpS
Links:
Dr. John Cush RheumNow ( View Tweet)
CAR-T Therapies in Antiphospholipid Antibody Syndrome
Dr. Putman and Dr. Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
https://t.co/VeAgl3qz8J https://t.co/rN4ZLM5Ft8
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe!
Rheum Manpower Needs - More Programs
https://t.co/xGXVFMkNra https://t.co/hcRGVMFZPE
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/PEPmzZPeFr https://t.co/sS7IiYW9PR
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/2QL2mz7Zhk https://t.co/YQ7jG1WnAG
Links:
Dr. John Cush RheumNow ( View Tweet)
View our interactive case study from the #SLEEducatorsNetwork to discover how you can apply the concept of disease modification to your patients with lupus. #Sponsored by GSK USMA
https://t.co/not76wZPnI https://t.co/Reot2JbWpF
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/11dneH04bv https://t.co/pp0ELe5mqV
Links:
Dr. John Cush RheumNow ( View Tweet)
NRMP Results for rheumatology 2022 :
- Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied)
- Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied)
WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/sqcIXxWrxx https://t.co/9xeUQeAuDD
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/ZcKU7MgXlm https://t.co/P9JBlxcdcx
Links:
Dr. John Cush RheumNow ( View Tweet)